Xeroderma Pigmentosum Clinical Trial
Official title:
A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients With Xeroderma Pigmentosum C and V (XPC and XPV)
The CUV152 study will evaluate the safety of afamelanotide in XP-C and XP-V patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00555633 -
Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients
|
N/A | |
| Recruiting |
NCT05159752 -
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
|
Phase 2 | |
| Recruiting |
NCT05484570 -
Natural History Study for DNA Repair Disorders
|
||
| Active, not recruiting |
NCT00001813 -
Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
|
||
| Completed |
NCT03445052 -
XPAND Trial: Enhancing XP Photoprotection Activities - New Directions
|
N/A | |
| Unknown status |
NCT01123694 -
Xeroderma Pigmentosum Patient Experiences
|
N/A | |
| Withdrawn |
NCT04500548 -
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
|
Phase 1 | |
| Enrolling by invitation |
NCT06330324 -
Reproductive Options in Inherited Skin Diseases
|
||
| Completed |
NCT00046189 -
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum
|